A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

Inclusion Criteria: * Confirmed diagnosis of CF * FEV1 at screening \>40 and \< 90% of predicted normal * History of PA infection in last 12 m * History of antibiotic treatment due tp PA infection (not for eradication) during last 12 m * Concomitant inhaled tobramycin, colistin, aztreonam, or levoflaxin (cycled or continuous) * Stable CF disease * Willing to remain on stable CF medication (Standard of care) * Women of child-bearing potential must habe negative urine pregnany test * Males \& females must use acceptable contraception * Capable of inhaling dry powder * willing to sign informed consent * willing and able to follow study procedures Exclusion Criteria: * Use of hypertonic saline \> twice daily * Clinically significant abnormal lab findings, except CRP. In case of high GGT values, case will be discussed by experts before deciding * History of comorbidity that may distort results or cause additional risk * pulmonary exacerbation within 28 days prior to randomisation * Change in CF therapy within 28 days prior to randomisation * Burkholderia spp. finding within 12 m prior to screening * pregnant or breast feeding females * History of allergic reactions to IMP ingredients, incl milk protein * Inability to perform lung function tests according to ATS/ ERS criteria * Uncontrolled or unstable diseases that might limit compliance * History of, or planned organ transplantation * Allergic ABPA in the last 12 months prior to the screening visit * Requirement for continuous oxygen supplementation * Current participation in another clinical study * medical condition, other than CFwhich exposes the patient to an unacceptably high risk * Concurrent mlignant disease, except BCC and cervical neoplasia * Clinically significant alcohol or drug abuse